What is Miyoes

Is this drug really necessary in animal husbandry?

8 out of 10

Livestrock breeders believe that the use of hormonal drugs has a negative effect of meat, but without them stimulating the growth of muscle mass in animals is impossible

10 out of 10

Breeders believe that for the growth of animal muscle mass, it is necessary to increase the amount of feed, which significantly increases the cost of keeping animals

Blocking myostatin in animals

The mechanism of action of the drug is based on the production in the body of animals of **auto-antibodies to the active receptor (ActRIIb)**, blocking its binding to myostatin and, as a consequence, accelerating the growth of animal muscles.

Blocking myostatin in animals

Mioyes is a recombinant protein in which a fragment of an activin receptor (ActRIIb) is attached to a carrier protein. The introduction of this drug to animals causes the formation of auto-antibodies to the receptor in the body. Auto-antibodies, specifically binding to the activin receptor (ActRIIb), block it from binding to myostatin, which leads to accelerated muscle growth. Mioyes does not block myostatin, but its interaction with the activin receptor.

Mioyes®

Is this drug really necessary in animal husbandry?

- Additional profit to the farmer up to 15%
- Reduction of animal mortality
- Cost-saving for livestock keeping
- Non GMO
- Safe final processed food
- Enhanced meat quality

Application of Miyoes

Sarcopenia (loss of muscle mass)

It highly affects physical activity levels. Lower physical activity levels also further contribute to muscle shrinkage.

Muscle atrophy and myopathy of various origins

It's usually caused by a lack of physical activity. The lack of mobility can result in muscle wasting.

Injuries leading to prolonged immobilization of muscle groups

it is necessary to carefully monitor the animals during the recovery period, as well as apply muscle growth stimulants.

Biological effects of injecting Mioyes

- Weight gain
- Increase in muscle mass
- An increase in the number of muscle cells
- Increase in muscle cell size
- Increased muscle strength
- Decrease in body fat
- Enlargement of genital tissue
- Increased appetite or feed intake
- Improving the physical condition of the animal
- An increase in bone and cartilage tissue

Clinical trial results

Increase in the weight gain of pigs during clinical trials, in kg



Increase in the daily weight gain of pigs during clinical trials, in gramm



Clinical trials of Mioyes showed

high efficiency of action, since the drug blocks **the activin receptor (ActRIIb)** and **does not require constant administration to the body** in high doses, like myostatin blockers;

the drug is **not hormonal in nature**, since only a fragment of the ActRIIb receptor is present in its composition;

the drug provides **long-term blocking of the activin receptor;**

there is extensive experience in the application of this approach with somatostatin antigens in agriculture antisom technology, which has shown its **safety and high efficiency** in a large sample of animals.

When the efficiency will be seen?

How mioyes works

First injection

21 days after the first injection, the weight of the pig in the clinical trials increased by 11.3% compared to the control group.

Second injection

21 days after the second injection, the weight of the pig in the clinical trials increased by 5% compared to the control group.

Final weight

By the time of the final weighing (64 days after the first injection), the pig's weight increased by 12% in comparison with the control group.

About Technopharm Investment

Company was established in 2018 in Scotland

The representative office was opened in Tashkent in 2019

The penetration to South East Asian market in 2021

The sales office was opened in Moscow in 2018

Technopharm Investments activities

- The company continually develop new drug formulations for both human and veterinary medicine;
- The company supplies human medical drugs across Central Asia and CIS;
- The company invented a revolutionary drug formula for treatment of animal distrophia;
- The company established trustful relationships with distributors across Central Asia and CIS since 2018

Technopharm Investments core values

HONESTY AND INTEGRITY

Each employee maintains the highest ethical standards and acts to protect and uphold the regulations and procedures required to produce quality drug products.

QUALITY AND SAFETY

The company is committed to producing safe and effective products, along with providing reliable information and service to our partners. We also have a strict guideline to all our stakeholders to be sure that CSR is maintained in accordance with the corporate culture.

INNOVATION AND CONTINUOUS IMPROVEMENT

Each employee has a "can do" attitude that manifests itself by creatively turning problems into solutions. This attitude is present at all levels in our company and is applied to all aspects of our operations. Each employee promotes and supports continuous efforts that lead to improvements in our processes, products, services and workplace.

The main strategies of the company for this year

- Introduction of our products to new markets.
- Expansion of a number of distributors on the global market.
- Enhancement of the company's footprint worldwide.

Contact us

UK office
64a Cumberland Street, Edinburgh, Scotland, EH3 6RE
Ph.No.: +44 7518 735822

Sales office in Russia
125167, Gabrichevskii st., 5, office 209, Moscow, Russia
Ph.No.: +7 915 443 1111

Representative office in Uzbekistan
100070, Bogidil st., 2A, Tashkent, Uzbekistan
Ph.No.: +998 90 902 20 01

Email: **info@technopharm.co.uk**